Mount Ridley Mines (ASX: MRD) reports 91.8% scandium recovery on half the reagent

Mount Ridley Mines' Selectro Test 3 achieved 91.8% scandium recovery, up from 80.0% in earlier tests, despite halving reagent dosage and using unbeneficiated ore under low-temperature, atmospheric-pressure conditions. Heavy and light rare-earth recoveries averaged 84% and 77%, respectively, with maximum recoveries reached in under four hours. The commissioned research note highlights Grass Patch's 47,357 tonnes of contained scandium and identifies third-party-feed validation and potential technology licensing as the next steps.

Analysis

This is not yet a valuation-changing metallurgical result: recovery alone says little about payable product economics without acid consumption, impurity rejection, residue handling, concentrate specification, and scale-up throughput. The key financial sensitivity is whether low-severity processing can reduce both initial capex and operating-cost volatility versus autoclave-based flowsheets; until an independent laboratory reproduces results on representative variability samples, the claimed process advantage should receive little credit in MRD's enterprise value.

The larger constraint is demand, not contained metal. Scandium's small, opaque end-market has historically prevented resource scale from translating into contracted cash flow, while gallium and heavy-rare-earth optionality requires separable, saleable products and customer qualification rather than headline recoveries. A cheaper flowsheet could eventually pressure the strategic scarcity premium attached to SRL and SCY, but only if MRD demonstrates impurity control and obtains offtake or third-party feed validation.

Near-term price action is likely dominated by promotional liquidity rather than fundamentals because the source is compensated by the issuer. Over the next 1-3 months, independent assay replication, reagent-consumption disclosure, and a preliminary flowsheet are the relevant catalysts; 6-18 month rerating requires pilot-scale recoveries, product specifications, and credible offtake. The thesis is falsified if repeat testing shows materially lower recovery across ore domains, reagent intensity rises at scale, or no commercial customer validates a scandium/gallium product pathway.

Key Decisions for Investors

• No new position in ASX:MRD or OTC:MRDMF on this release; treat any liquidity-driven spike as non-fundamental until independent third-party metallurgical work publishes acid consumption, impurity deportment, and scale-up mass balance.
• Create a catalyst alert on MRD for third-party-feed validation or pilot results within 1-3 months. Reassess only if results include recoveries across multiple composites, product-grade specifications, and a preliminary capex/opex comparison versus pressure-leach alternatives.
• Monitor ASX:SRL and TSX:SCY as relative-value read-throughs rather than immediate shorts: a verified low-capex alternative could compress their process-moat premium, but their more advanced engineering, permitting, and customer-validation positions remain materially more valuable than a bench-scale recovery claim.
• For any future MRD long, require evidence of commercial demand—binding offtake, qualification samples, or a credible scandium/gallium pricing framework—as the risk/reward is otherwise governed by a thin market rather than resource or recovery scale.